Identification and Management of Peripartum Depression.

Area of Science:

• Obstetrics and Gynecology
• Psychiatry
• Public Health

Background:

• Peripartum depression affects up to 1 in 7 women, posing risks to maternal and neonatal health.
• A history of depression is the primary risk factor for developing peripartum depression.
• Screening for depression in pregnant and postpartum women is recommended by the U.S. Preventive Services Task Force.

Purpose of the Study:

• To review effective screening strategies for peripartum depression.
• To differentiate peripartum depression from the 'baby blues'.
• To outline management and treatment options for peripartum depression.

Main Methods:

• Literature review of screening, diagnosis, and treatment of peripartum depression.
• Distinguishing peripartum depression from transient mood changes.
• Evaluating safety of selective serotonin reuptake inhibitors (SSRIs) during pregnancy and breastfeeding.

Main Results:

• Both one-step and two-step screening methods effectively identify peripartum depression.
• Peripartum depression requires distinct management from the 'baby blues'.
• Specific SSRIs (citalopram, escitalopram, sertraline) are safer in pregnancy; others (fluvoxamine, paroxetine, sertraline) preferred during breastfeeding.

Conclusions:

• Early identification and intervention are crucial for managing peripartum depression.
• Treatment approaches vary based on severity, including psychotherapy and pharmacotherapy.
• Urgent psychiatric consultation is necessary for severe cases involving psychosis or suicidal ideation.